Spots Global Cancer Trial Database for target therapy
Every month we try and update this database with for target therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM | NCT03127072 | Colorectal Canc... | Radiofrequency ... chemotherapy ± ... | 18 Years - 75 Years | Fudan University | |
| Mobile Health Application of Disease Self-Management in Non-Small Cell Lung Cancer Patients During Targeted Therapy | NCT05611450 | Non-small Cell ... | disease self-ma... | 20 Years - | Chang Gung Memorial Hospital | |
| Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM | NCT03127072 | Colorectal Canc... | Radiofrequency ... chemotherapy ± ... | 18 Years - 75 Years | Fudan University | |
| Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment | NCT06032728 | Renal Cell Carc... | Sunitinib | 18 Years - 75 Years | First Affiliated Hospital, Sun Yat-Sen University | |
| Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC | NCT05229003 | Metastatic Colo... | Anlotinib Penpulimab Irinotecan | 18 Years - 85 Years | Fudan University | |
| Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer | NCT04582981 | Advanced Colore... | Fruquintinib an... Fruquintinib | 18 Years - | Fudan University | |
| Combination of Nimotuzumab,Capecitabine and Radiotherapy for Inoperable or Recurrent Gastric Cancer | NCT01180166 | Gastric Cancer Concurrent Chem... | nimotuzumab | 18 Years - 75 Years | ChineseAMS | |
| Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer | NCT05095636 | Gastric Cancer Metastasis | Apatinib Mesyla... Camrelizumab | 18 Years - 75 Years | Fudan University | |
| TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma | NCT05247996 | Intrahepatic Ch... | Transcatheter a... Multi-target Dr... Immunocheckpoin... Systemic Intrav... | 18 Years - | The Central Hospital of Lishui City | |
| TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma | NCT05247996 | Intrahepatic Ch... | Transcatheter a... Multi-target Dr... Immunocheckpoin... Systemic Intrav... | 18 Years - | The Central Hospital of Lishui City | |
| Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM | NCT03125161 | Colorectal Aden... | HAI chemotherapy ± ... | 18 Years - 75 Years | Fudan University | |
| Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer | NCT04582981 | Advanced Colore... | Fruquintinib an... Fruquintinib | 18 Years - | Fudan University | |
| A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer | NCT05257122 | Advanced Pancre... | Fruquintinib | 18 Years - 80 Years | Fudan University | |
| BAY73-4506 Probe Substrate Study | NCT01287598 | Neoplasms | Regorafenib (St... Warfarin Omeprazole Midazolam Rosiglitazone | 18 Years - | Bayer | |
| Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM | NCT03125161 | Colorectal Aden... | HAI chemotherapy ± ... | 18 Years - 75 Years | Fudan University | |
| The Impact of Targeted Therapy on Microorganism in Patients With Psoriasis | NCT01504113 | Psoriasis | 20 Years - 90 Years | National Taiwan University Hospital | ||
| Mobile Health Application of Disease Self-Management in Non-Small Cell Lung Cancer Patients During Targeted Therapy | NCT05611450 | Non-small Cell ... | disease self-ma... | 20 Years - | Chang Gung Memorial Hospital | |
| Selective Treatment According to Molecular Subtype of Prostate Cancer | NCT03696186 | Castration-resi... Prostate Cancer... | Luminal type-1 Luminal type-2 Neuroendocrine ... Neuroendocrine ... Atypical type-1 Atypical type-2 | 18 Years - | Tianjin Medical University Second Hospital | |
| Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC | NCT05229003 | Metastatic Colo... | Anlotinib Penpulimab Irinotecan | 18 Years - 85 Years | Fudan University | |
| In Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumor | NCT06246630 | Advanced Pancre... | Chemotherapy an... | 18 Years - 75 Years | Ruijin Hospital | |
| Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy | NCT03724097 | Cancer | RNA sequencing Transcriptome a... target drug wit... target drug wit... non-target drug palliative care | 18 Years - 80 Years | OmicsWay Corp. | |
| Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer | NCT05095636 | Gastric Cancer Metastasis | Apatinib Mesyla... Camrelizumab | 18 Years - 75 Years | Fudan University | |
| A Pilot Study on ALK Gene Mutations in Neuroblastoma | NCT01986595 | Neuroblastoma | - 50 Years | National Taiwan University Hospital | ||
| BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study) | NCT04839471 | Esophageal Squa... | BI-754091 plus ... | 20 Years - | National Health Research Institutes, Taiwan | |
| Sorafenib in Relapsed High Grade Osteosarcoma | NCT00889057 | Osteosarcoma | sorafenib | 15 Years - 75 Years | Italian Sarcoma Group | |
| Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer | NCT04582981 | Advanced Colore... | Fruquintinib an... Fruquintinib | 18 Years - | Fudan University | |
| Selective Treatment According to Molecular Subtype of Prostate Cancer | NCT03696186 | Castration-resi... Prostate Cancer... | Luminal type-1 Luminal type-2 Neuroendocrine ... Neuroendocrine ... Atypical type-1 Atypical type-2 | 18 Years - | Tianjin Medical University Second Hospital | |
| A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer | NCT05257122 | Advanced Pancre... | Fruquintinib | 18 Years - 80 Years | Fudan University | |
| Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma | NCT05844813 | Retroperitoneal... | Doxorubicin+Ifo... Radical Surgery | 18 Years - 75 Years | Peking University International Hospital | |
| A Pilot Study on ALK Gene Mutations in Neuroblastoma | NCT01986595 | Neuroblastoma | - 50 Years | National Taiwan University Hospital | ||
| Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma | NCT05844813 | Retroperitoneal... | Doxorubicin+Ifo... Radical Surgery | 18 Years - 75 Years | Peking University International Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
